WallStreetZenWallStreetZen

NASDAQ: EPRX
Eupraxia Pharmaceuticals Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for EPRX

Based on 2 analysts offering 12 month price targets for Eupraxia Pharmaceuticals Inc

Min Forecast
$11.00+75.44%
Avg Forecast
$11.50+83.41%
Max Forecast
$12.00+91.39%

Should I buy or sell EPRX stock?

Based on 2 analysts offering ratings for Eupraxia Pharmaceuticals Inc.

Strong Buy
Strong Buy
1 analysts 50%
Buy
1 analysts 50%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although EPRX's forecast from analysts indicates a "Strong Buy", our proven Zen Rating quant model rates EPRX as a "Hold". Stocks with a Zen Rating of Hold have had an average return of +7.53% per year. Learn More

Be the first to know when Wall Street analysts revise their EPRX stock forecasts and price targets.

EPRX stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2025-08-20
lockedlocked$00.00+00.00%2025-07-24

1 of 1

Forecast return on equity

Is EPRX forecast to generate an efficient return?

Company
-26.33%
Industry
252.48%
Market
227.91%
EPRX's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is EPRX forecast to generate an efficient return on assets?

Company
-25.66%
Industry
90.65%
EPRX is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

EPRX earnings per share forecast

What is EPRX's earnings per share in the next 3 years based on estimates from 6 analysts?

Avg 1 year Forecast
-$0.84
Avg 2 year Forecast
-$0.76
Avg 3 year Forecast
-$0.41

EPRX revenue forecast

What is EPRX's revenue in the next 3 years based on estimates from 5 analysts?

Avg 1 year Forecast
$0.0
Avg 2 year Forecast
$0.0
Avg 3 year Forecast
$45.3M

EPRX vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
EPRX$6.27$11.50+83.41%Strong Buy
TNXP$19.28N/AN/A
CABA$2.36$14.60+518.64%Strong Buy
RNAC$8.52$37.33+338.18%Strong Buy
TARA$5.70$23.00+303.51%Buy
View Top Biotech Stocks

Eupraxia Pharmaceuticals Stock Forecast FAQ

Is Eupraxia Pharmaceuticals Stock a good buy in 2025, according to Wall Street analysts?

The consensus among 2 Wall Street analysts covering (NASDAQ: EPRX) stock is to Strong Buy EPRX stock.

Out of 2 analysts, 1 (50%) are recommending EPRX as a Strong Buy, 1 (50%) are recommending EPRX as a Buy, 0 (0%) are recommending EPRX as a Hold, 0 (0%) are recommending EPRX as a Sell, and 0 (0%) are recommending EPRX as a Strong Sell.

If you're new to stock investing, here's how to buy Eupraxia Pharmaceuticals stock.

What is EPRX's earnings growth forecast for 2025-2027?

(NASDAQ: EPRX) Eupraxia Pharmaceuticals's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 43.76%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 42.6%.

Eupraxia Pharmaceuticals's earnings in 2025 is -$29,416,658.On average, 6 Wall Street analysts forecast EPRX's earnings for 2025 to be -$30,152,098, with the lowest EPRX earnings forecast at -$39,264,252, and the highest EPRX earnings forecast at -$20,007,904. On average, 6 Wall Street analysts forecast EPRX's earnings for 2026 to be -$27,365,231, with the lowest EPRX earnings forecast at -$31,309,996, and the highest EPRX earnings forecast at -$18,957,884.

In 2027, EPRX is forecast to generate -$14,732,635 in earnings, with the lowest earnings forecast at -$37,818,678 and the highest earnings forecast at $28,034,079.

What is EPRX's revenue growth forecast for 2025-2027?

(NASDAQ: EPRX) Eupraxia Pharmaceuticals's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 101.28%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 25.61%.

Eupraxia Pharmaceuticals's revenue in 2025 is $0.On average, 5 Wall Street analysts forecast EPRX's revenue for 2025 to be $0, with the lowest EPRX revenue forecast at $0, and the highest EPRX revenue forecast at $0. On average, 5 Wall Street analysts forecast EPRX's revenue for 2026 to be $0, with the lowest EPRX revenue forecast at $0, and the highest EPRX revenue forecast at $0.

In 2027, EPRX is forecast to generate $1,627,278,331 in revenue, with the lowest revenue forecast at $0 and the highest revenue forecast at $4,836,561,896.

What is EPRX's forecast return on assets (ROA) for 2025-2028?

(NASDAQ: EPRX) forecast ROA is -25.66%, which is lower than the forecast US Biotechnology industry average of 90.65%.

What is EPRX's Price Target?

According to 2 Wall Street analysts that have issued a 1 year EPRX price target, the average EPRX price target is $11.50, with the highest EPRX stock price forecast at $12.00 and the lowest EPRX stock price forecast at $11.00.

On average, Wall Street analysts predict that Eupraxia Pharmaceuticals's share price could reach $11.50 by Aug 20, 2026. The average Eupraxia Pharmaceuticals stock price prediction forecasts a potential upside of 83.41% from the current EPRX share price of $6.27.

What is EPRX's Earnings Per Share (EPS) forecast for 2025-2027?

(NASDAQ: EPRX) Eupraxia Pharmaceuticals's current Earnings Per Share (EPS) is -$0.88. On average, analysts forecast that EPRX's EPS will be -$0.84 for 2025, with the lowest EPS forecast at -$1.09, and the highest EPS forecast at -$0.56. On average, analysts forecast that EPRX's EPS will be -$0.76 for 2026, with the lowest EPS forecast at -$0.87, and the highest EPS forecast at -$0.53. In 2027, EPRX's EPS is forecast to hit -$0.41 (min: -$1.05, max: $0.78).

What is EPRX's forecast return on equity (ROE) for 2025-2028?

(NASDAQ: EPRX) forecast ROE is -26.33%, which is considered weak.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.